VXRT
- Vaxart, Inc.
()
Overview
Company Summary
Vaxart, Inc. is a company focused on the development of oral recombinant vaccines. Their goal is to create a new generation of vaccines that can be administered orally, eliminating the need for injections. This approach offers multiple advantages such as increased convenience, improved patient compliance, and potentially enhanced immune responses.
Vaxart's proprietary technology platform utilizes adenovirus-based vectors to deliver the vaccine antigens directly into the mucosal surfaces of the body, primarily the gut. By doing so, the vaccine can stimulate a broad range of immune responses, including both systemic and mucosal immunity. This is particularly important as certain infections, such as respiratory and gastrointestinal viruses, primarily target mucosal surfaces.
The company's vaccine candidates cover a wide range of diseases, including influenza, respiratory syncytial virus (RSV), norovirus, and coronavirus. Vaxart is actively engaged in the development and clinical testing of these oral vaccine candidates, with the ultimate goal of providing effective and accessible solutions to prevent and control infectious diseases.
In addition to their vaccine pipeline, Vaxart also collaborates with pharmaceutical and biotechnology companies to apply their oral vaccine technology to their partners' specific targets. This collaboration model allows Vaxart to leverage its expertise and platform to address a broader range of infectious diseases and expand the potential impact of their technology.
Through their innovative approach and commitment to addressing unmet medical needs, Vaxart aims to revolutionize the way vaccines are administered and contribute to the prevention and control of infectious diseases worldwide.